ULTRAGENYX PHARMACEUTICAL INC. Cash and Cash Equivalents
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Cash and Cash Equivalents of $125.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $125.00M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $175.00M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $421.00M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $202.51M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $125.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $175.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $421.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $202.51M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $176.00M 10-Q · filed 2026-08-05 | $176.31M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $127.00M 10-Q · filed 2026-05-06 | $127.06M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $174.00M 10-K · filed 2026-02-18 | $173.73M 10-K · filed 2025-02-19 |
| 2024-09-30 | $150.62M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $480.69M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $112.25M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $214.00M 10-K · filed 2026-02-18 | $213.58M 10-K · filed 2024-02-21 |
| 2023-09-30 | $72.58M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $102.06M 10-Q · filed 2024-08-02 | |
| 2023-03-31 | $85.77M 10-Q · filed 2024-05-03 | |
| 2022-12-31 | $132.94M 10-K · filed 2025-02-19 | |
| 2022-09-30 | $391.65M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $159.87M 10-Q · filed 2023-08-04 | |
| 2022-03-31 | $153.99M 10-Q · filed 2023-05-05 | |
| 2021-12-31 | $307.58M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $197.54M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $290.88M 10-Q · filed 2022-07-29 | |
| 2021-03-31 | $383.79M 10-Q · filed 2022-05-06 | |
| 2020-12-31 | $713.53M 10-K · filed 2023-02-17 | |
| 2020-09-30 | $197.49M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $335.64M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $298.19M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $433.58M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $122.58M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $131.34M 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $269.71M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $113.43M 10-K · filed 2021-02-12 | |
| 2018-09-30 | $82.96M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $110.85M 10-Q · filed 2019-08-02 | |
| 2018-03-31 | $226.73M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $100.49M 10-K · filed 2020-02-14 | |
| 2017-09-30 | $60.41M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $90.75M 10-Q · filed 2018-08-03 | |
| 2017-03-31 | $159.50M 10-Q · filed 2018-05-08 | |
| 2016-12-31 | $161.12M 10-K · filed 2019-02-20 | |
| 2016-09-30 | $142.28M 10-Q · filed 2017-11-03 | |
| 2016-06-30 | $55.07M 10-Q · filed 2017-07-28 | |
| 2016-03-31 | $70.76M 10-Q · filed 2017-05-05 | |
| 2015-12-31 | $93.57M 10-K · filed 2018-02-21 | |
| 2015-09-30 | $166.69M 10-Q · filed 2016-11-08 | |
| 2015-06-30 | $52.35M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $178.04M 10-Q · filed 2016-05-10 | |
| 2014-12-31 | $24.32M 10-K · filed 2018-02-21 | |
| 2014-09-30 | $53.39M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $17.45M 10-Q · filed 2015-08-14 | |
| 2014-03-31 | $55.45M 10-Q · filed 2015-05-12 | |
| 2013-12-31 | $7.43M 10-K · filed 2017-02-17 | |
| 2013-09-30 | $6.05M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $13.51M 10-Q · filed 2014-08-11 | |
| 2013-03-31 | $64.80M 10-Q · filed 2014-05-12 | |
| 2012-12-31 | $86.19M 10-K · filed 2016-02-26 | |
| 2011-12-31 | $10.64M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |